In particular, neither PF-04236921 (a fully human antibody specifically binding IL-6 ligand) was superior to placebo in patients with SLE9 nor did sirukumab demonstrate any benefit in patients with active lupus nephritis and persistent proteinuria.10 Inhibiting IL-6R with vobarilizumab (ALX-0061) did not meet the primary endpoint of dose response in patients with active SLE.72 Likewise, TCZ failed to show clinical improvement in patients with refractory adult polymyositis and dermatomyositis73 as well as in patients with pSS with moderate or high systemic disease activity.11 This evidence concerns the gene IL6R and polymyositis.